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Abstract
Psoriasis is a chronic skin condition that is initiated by an intense immune system. Erythrodermic Psoriasis
(EP) is an aggressive and inflammatory form, though it is uncommon among patients. The main symptom is
a peeling rash on the body’s whole surface. The rash itches and burns and spreads very rapidly. This type of
psoriasis affects more than 75% of the surface of the body with inflammation and with/without exfoliation. It
may be seen in association with psoriasis of Von Zumbusch pustular type. It is normally seen in people who have
plaque psoriasis. EP generally makes the skin to lose its capacity to regulate body temperature and to protect
against infections. In the beginning, the treatment generally includes a topical application of a combination of
medium potent steroids and moisturizers along with wet dressings and oatmeal baths. Bed rest is also suggested.
Usually it is advised to maintain and restore body fluids. General systemic therapies include the administration
of methotrexate, cyclosporine and retinoid.
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Introduction
Erythrodermic Psoriasis (EP) is an uncommon
but severe type of Psoriasis. Its prevalence among
the patients with psoriasis is about 1–2.25%.1 The
current therapy available for the management of EP,
including medium potency topical corticosteroids
and moisturizers, shows unsatisfactory outcomes,
hence, its management remains as a challenge for
physicians. There are multiple documented and
emerging causes of EP. It may arise from a previous
history of any type of psoriasis at any age. EP also
generally occurs due to microbial infections. Various
drugs like antimalarial agents, trimethoprim, lithium
and sulfamethoxazole, and environmental factors
such as psychological and metabolic factors may also
play a considerable role.2
At the initial level, the inﬂammation of the skin in
erythroderma produces vasodilation and ensuing
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thermoregulatory disturbances. Later, shunting of
blood combined with exfoliative losses will result in
increased transpiration and ﬂuid losses, increasing
the risk of septicaemia of Staphylococcus aureus.
Due to these ﬂuid losses and shunting, multiple
electrolyte abnormalities and organ hypoperfusion
effects can be observed.3
The characteristics of the disease are erythema,
edema desquamation along with several
symptoms such as tachycardia, fatigue, malaise,
fever, chills, dehydration, electrolyte imbalance,
lymphadenopathy, arthralgia, myalgia, insomnia,
sweat, diarrhea, constipation, weight changes, etc,.
However, rarely, a high output heart failure (maybe
because of excessive water loss and edema) and
cachexia may also be seen.2 It is a potentially fatal
disease as most of the patients are elderly and the skin
involvement is widespread.1 EP has life-threatening
complications such as hemodynamic, metabolic,
immunologic, infectious, and thermoregulatory
disturbances.3
Case report
A 13-year-old boy was presented with itchy lesions
over the knee and elbow one month ago, which
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Figure 1: Severe skin desquamation over the entire body on 2nd day of admission.

then progressed to the body and scalp overall. The
lesions started peeling and crusting gradually, and
the patient also had a history of an on and off fever
and body pains for the last month.
The boy was febrile on admission with moderate
distress and had signs of moderate dehydration
associated with severe malnutrition. Generalized
skin redness and desquamation were seen over his
entire body surface except on his face. There was
no history of consanguinity, pathological, and
none of the other family members affected by the
same disorder. The patient was diagnosed with
plaque psoriasis and had been treated with topical
corticosteroids and moisturizing creams. He visited
our hospital several times with similar complaints
for the last six years with exacerbations during
winter.

elevated, though the chest X-ray was normal. Based
on the subjective and objective evidence, the patient
was clinically diagnosed with severe erythrodermic
psoriasis. Induction therapy with corticosteroids,
methotrexate, emollients and antihistamines was
prescribed. Adverse events have not been observed
during the entire course of treatment.
Discussion
EP is a rare but dangerous type of psoriasis, which is
noticed by erythema of the whole body with scaling;
furthermore, it is associated with considerable
mortality incidences.2 Enormous loss in protein and
fluids, leucocytosis, anaemia, increased C-reactive
protein and erythrocyte sedimentation rate,
electrolyte abnormalities, temperature irregularities,
abnormal liver function are generally observed in
this type of psoriasis.1,4
There is a deficiency of excellent medical literature
on the examination and treatment options for
erythrodermic psoriasis. Previous clinical trials have
shown that systemic agents such as cyclosporin A
or methotrexate should be started as soon as the
disease is diagnosed. New immunomodulators like
alefacept, efalizumab, etanercept and infliximab are
recommended in mild cases, though they are used
less in severe cases.5 Other agents like corticosteroids
and emollients play a major role in treating this type
of psoriasis.

Figure 2: Significant changes after 13 days of treatment

Laboratory tests showed decreased haemoglobin
levels (10.8 gm%), increased neutrophil (78%) and
eosinophil (8%) count; on liver function tests it is
observed that SGPT, SGOT and ALT levels were
72

The patient was prescribed with Corticosteroids
[tab. Methylprednisolone (8mg BD), Clonate –F
lotion (clobetasol + fusidic acid), Topisal lotion
(clobetasol + salicylic acid)], Emollient [Aquadew
lotion (Glycerin)], tab. Methotrexate (2.5mg BD),
Anti-histamine [tab. Levocetrizine (10mg OD),
tab. hydroxyzine (10mg OD)], and other drugs
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like antibiotics [inj. Ceftriaxone (500mg BD), inj.
Amikacin (250mg OD), and H2 receptor antagonist
[inj. Ranitidine (150mg BD)] were also prescribed.
The patient was also prescribed with syrup livogen to
bring his liver enzymes to normal. After four days of
admission, it was observed that all the liver function
tests like SGPT, SGOT & ALT levels had reached
normal. A significant improvement was observed
after 13 days as indicated by the disappearance of
psoriatic lesions all over the body.
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